EUVIMEDEUVIMED entdecken
Crossref

L26/O-070 Intraovarian platelet-rich plasma in poor ovarian reserve: does route of administration influence ovarian responsiveness and feasibility?

H. Dj, D.R. Gedela, K. Chaitanya, N. Balkawade, S. Vellanki, P.K. Nayak

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von H. Dj und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question In women with poor ovarian reserve, does the route of intraovarian platelet-rich plasma (PRP) administration influence post-treatment ovarian responsiveness and reproductive feasibility? Summary answer Intraovarian PRP was associated with improved ovarian responsiveness in POSEIDON 3–4 women, with comparable downstream reproductive outcomes following laparoscopic and transvaginal administration. What is known already Poor ovarian reserve is characterised by diminished follicular activity and poor response to stimulation. Autologous platelet-rich plasma (PRP) has been proposed as a biological modulator of the ovarian microenvironment, but evidence remains limited and heterogeneous. While intraovarian PRP has been delivered via laparoscopic and transvaginal routes, comparative data evaluating whether route of administration influences ovarian or reproductive outcomes are scarce. Clarifying feasibility and comparability of delivery routes is essential before wider evaluation of efficacy. Study design, size, duration This prospective interventional cohort study was conducted between 2023 and 2025 at a tertiary fertility centre following ethics approval and trial registration. A total of 129 women with poor ovarian reserve (POSEIDON Groups 3–4) underwent intraovarian autologous PRP administration, delivered laparoscopically (n = 26) or via transvaginal ultrasound guidance (n = 103), and were followed through subsequent ovarian stimulation and reproductive outcomes. Participants/materials, setting, methods Autologous PRP was prepared from peripheral blood using a standardised double-spin protocol and injected into the ovarian cortex. Ovarian stimulation was initiated 1–3 months post-PRP. Primary outcomes focused on ovarian responsiveness, including antral follicle count (AFC), oocyte yield, number of mature (MII) oocytes, and embryo formation. Secondary outcomes included fertilisation, implantation, clinical pregnancy, live birth, and spontaneous conception. Outcomes were analysed descriptively and by route of administration. Main results and the role of chance Following PRP administration, 93% of women demonstrated an increase in AFC. The proportion of women with no detectable AFC declined from 6.9% to 0% (p = 0.003). Cycles with no oocyte retrieval decreased from 13.5% to 1.8% (p = 0.001), absence of mature oocytes from 12.5% to 2.7% (p = 0.007), and failure of embryo formation from 72.6% to 22.1% (p < 0.001). Among women proceeding to frozen embryo transfer (n = 45), implantation, clinical pregnancy, and live birth rates were 31.3%, 53.3%, and 46.6%, respectively. No statistically significant differences were observed between laparoscopic and transvaginal PRP administration across ovarian or reproductive outcomes, indicating comparable feasibility of both routes. Limitations, reasons for caution The study lacked a non-PRP control group, was non-randomised with unequal subgroup sizes, and was not designed to establish efficacy. Regression to the mean and stimulation-related confounding cannot be excluded. Findings should be interpreted as exploratory. Wider implications of the findings Intraovarian PRP may enhance ovarian response and embryo development in women with poor ovarian reserve. Comparable outcomes between laparoscopic and transvaginal routes support the feasibility of the less invasive transvaginal approach, while emphasizing the need for randomized trials to clarify efficacy, mechanisms, and patient selection. Trial registration number Yes

Zitieren

APA

Dj, H., Gedela, D., Chaitanya, K., Balkawade, N., Vellanki, S., & Nayak, P. (2026). L26/O-070 Intraovarian platelet-rich plasma in poor ovarian reserve: does route of administration influence ovarian responsiveness and feasibility?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.070

Vancouver

Dj H, Gedela D, Chaitanya K, Balkawade N, Vellanki S, Nayak P. L26/O-070 Intraovarian platelet-rich plasma in poor ovarian reserve: does route of administration influence ovarian responsiveness and feasibility?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.070

BibTeX
@article{Dj2026,
  author = {Dj, H. and Gedela, D.R. and Chaitanya, K. and Balkawade, N. and Vellanki, S. and Nayak, P.K.},
  title = {L26/O-070 Intraovarian platelet-rich plasma in poor ovarian reserve: does route of administration influence ovarian responsiveness and feasibility?},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.070}
}
Kostenlos starten →